Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters










Publication year range
1.
ACS Omega ; 9(16): 18169-18182, 2024 Apr 23.
Article in English | MEDLINE | ID: mdl-38680351

ABSTRACT

Alzheimer's disease (AD) is a multifactorial and emerging neurological disorder, which has invoked researchers to develop multitargeted ligands. Herein, hybrid conjugates of 5-phenyl-1,3,4-oxadiazole and piperazines were rationally designed, synthesized, and pharmacologically evaluated against hAChE, hBChE, and hBACE-1 enzymes for the management of AD. Among the series, compound 5AD comprising pyridyl substitution at terminal nitrogen of piperazine contemplated as a paramount lead compound (hAChE, IC50 = 0.103 ± 0.0172 µM, hBChE, IC50 ≥ 10 µM, and hBACE-1, IC50 = 1.342 ± 0.078 µM). Compound 5AD showed mixed-type enzyme inhibition in enzyme kinetic studies against the hAChE enzyme. In addition, compound 5AD revealed a significant displacement of propidium iodide from the peripheral anionic site (PAS) of hAChE and excellent blood-brain barrier (BBB) permeability in a parallel artificial membrane permeation assay (PAMPA). Besides, 5AD also exhibited anti-Aß aggregation activity in self- and AChE-induced thioflavin T assay. Further, compound 5AD has shown significant improvement in learning and memory (p < 0.001) against the in vivo scopolamine-induced cognitive dysfunction mice model. The ex vivo study implied that after treatment with compound 5AD, there was a decrease in AChE and malonaldehyde (MDA) levels with an increase in catalase (CAT, oxidative biomarkers) in the hippocampal brain homogenate. Hence, compound 5AD could be regarded as a lead compound and further be explored in the treatment of AD.

2.
J Cell Mol Med ; 26(7): 2119-2131, 2022 04.
Article in English | MEDLINE | ID: mdl-35152538

ABSTRACT

Alcohol is a risk factor for hepatocellular carcinoma (HCC). However, the molecular mechanism by which chronic alcohol consumption contributes to HCC is not well understood. The purpose of the study was to demonstrate the effects of chronic ethanol exposure on the damage of human normal hepatocytes. Our data showed that chronic exposure of hepatocytes with ethanol induced changes similar to transformed hepatocytes that is, exhibited colonies and anchorage-independent growth. These damaged hepatocytes contained high levels of reactive oxygen species (ROS) and showed induction of the SATB2 gene. Furthermore, damaged hepatocytes gained the phenotypes of CSCs which expressed stem cell markers (CD133, CD44, CD90, EpCAM, AFP and LGR5), and pluripotency maintaining factors (Sox-2, POU5F1/Oct4 and KLF-4). Ethanol exposure also induced Nanog, a pluripotency maintaining transcription factor that functions in concert with Oct4 and SOX-2. Furthermore, ethanol induced expression of EMT-related transcription factors (Snail, Slug and Zeb1), N-Cadherin, and inhibited E-cadherin expression in damaged hepatocytes. Ethanol enhanced recruitment of SATB2 to promoters of Bcl-2, Nanog, c-Myc, Klf4 and Oct4. Ethanol also induced activation of the Wnt/TCF-LEF1 pathway and its targets (Bcl-2, Cyclin D1, AXIN2 and Myc). Finally, ethanol induced hepatocellular steatosis, SREBP1 transcription, and modulated the expression of SREBP1c, ACAC, ACLY, FASN, IL-1ß, IL-6, TNF-α, GPC3, FLNB and p53. These data suggest that chronic alcohol consumption may contribute towards the development of HCC by damaging normal hepatocytes with the generation of inflammatory environment, induction of SATB2, stem cell-like characteristics, and cellular steatosis.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Matrix Attachment Region Binding Proteins , Carcinoma, Hepatocellular/chemically induced , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/metabolism , Epithelial-Mesenchymal Transition/genetics , Ethanol/toxicity , Glypicans/metabolism , Hepatocytes/metabolism , Humans , Lipogenesis , Liver Neoplasms/pathology , Matrix Attachment Region Binding Proteins/genetics , Matrix Attachment Region Binding Proteins/metabolism , Neoplastic Stem Cells/metabolism , Oxidative Stress , Transcription Factors/metabolism
3.
Bioorg Chem ; 119: 105562, 2022 02.
Article in English | MEDLINE | ID: mdl-34952243

ABSTRACT

Alzheimer's disease (AD) is a progressive neurological illness that causes dementia mainly in the elderly. The challenging obstacles related to AD has freaked global healthcare system to encourage scientists in developing novel therapeutic startegies to overcome with the fatal disease. The current treatment therapy of AD provides only symptomatic relief and to some extent disease-modifying effects. The current approach for AD treatment involves designing of cholinergic inhibitors, Aß disaggregation inducing agents, tau inhibitors and several antioxidants. Hence, extensive research on AD therapy urgently requires a deep understanding of its pathophysiology and exploration of various chemical scaffolds to design and develop a potential drug candidate for the treatment. Various issues linked between disease and therapy need to be considered such as BBB penetration capability, clinical failure and multifaceted pathophisiology requires a proper attention to develop a lead candidate. This review article covers all probable mechanisms including one of the recent areas for investigation i.e., lipid dyshomeostasis, pathogenic involvement of P. gingivalis and neurovascular dysfunction, recently reported molecules and drugs under clinical investigations and approved by FDA for AD treatment. Our summarized information on AD will attract the researchers to understand and explore current status and structural modifications of the recently reported heterocyclic derivatives in drug development for AD therapy.


Subject(s)
Alzheimer Disease/drug therapy , Anti-Bacterial Agents/pharmacology , Heterocyclic Compounds/pharmacology , Neuroprotective Agents/pharmacology , Porphyromonas gingivalis/drug effects , Alzheimer Disease/metabolism , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Humans , Microbial Sensitivity Tests , Molecular Structure , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/chemistry
4.
J Biomol Struct Dyn ; 39(12): 4510-4521, 2021 Aug.
Article in English | MEDLINE | ID: mdl-32568012

ABSTRACT

COVID-19 has ravaged the world and is the greatest of pandemics in modern human history, in the absence of treatment or vaccine, the mortality and morbidity rates are very high. The present investigation identifies potential leads from the plant Withania somnifera (Indian ginseng), a well-known antiviral, immunomodulatory, anti-inflammatory and a potent antioxidant plant, using molecular docking and dynamics studies. Two different protein targets of SARS-CoV-2 namely NSP15 endoribonuclease and receptor binding domain of prefusion spike protein from SARS-CoV-2 were targeted. Molecular docking studies suggested Withanoside X and Quercetin glucoside from W. somnifera have favorable interactions at the binding site of selected proteins, that is, 6W01 and 6M0J. The top-ranked phytochemicals from docking studies, subjected to 100 ns molecular dynamics (MD) suggested Withanoside X with the highest binding free energy (ΔGbind = -89.42 kcal/mol) as the most promising inhibitor. During MD studies, the molecule optimizes its conformation for better fitting with the receptor active site justifying the high binding affinity. Based on proven therapeutic, that is, immunomodulatory, antioxidant and anti-inflammatory roles and plausible potential against n-CoV-2 proteins, Indian ginseng could be one of the alternatives as an antiviral agent in the treatment of COVID 19. Communicated by Ramaswamy H. Sarma.


Subject(s)
COVID-19 , Panax , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation , SARS-CoV-2
5.
J Cell Mol Med ; 24(14): 7706-7716, 2020 07.
Article in English | MEDLINE | ID: mdl-32458441

ABSTRACT

The incidence of obesity and type 2 diabetes (T2DM) in the Western world has increased dramatically during the recent decades. According to the American Cancer Society, pancreatic cancer (PC) is the fourth leading cause of cancer-related death in the United States. The relationship among obesity, T2DM and PC is complex. Due to increase in obesity, diabetes, alcohol consumption and sedentary lifestyle, the mortality due to PC is expected to rise significantly by year 2040. The underlying mechanisms by which diabetes and obesity contribute to pancreatic tumorigenesis are not well understood. Furthermore, metabolism and microenvironment within the pancreas can also modulate pancreatic carcinogenesis. The risk of PC on a population level may be reduced by modifiable lifestyle risk factors. In this review, the interactions of diabetes and obesity to PC development were summarized, and novel strategies for the prevention and treatment of diabetes and PC were discussed.


Subject(s)
Diabetes Mellitus, Type 2/complications , Disease Susceptibility , Obesity/complications , Pancreatic Neoplasms/etiology , Animals , Biomarkers , Cellular Microenvironment/immunology , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Disease Management , Humans , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Mutation , Obesity/drug therapy , Obesity/metabolism , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/prevention & control , Risk Assessment , Risk Factors
6.
Assay Drug Dev Technol ; 17(6): 285-291, 2019 08.
Article in English | MEDLINE | ID: mdl-31532713

ABSTRACT

In silico molecular docking is an efficient technique for drug design that predicts the optimized orientation of the ligand against a specific drug target. This is a cost-effective and time-saving technique that requires limited manpower. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed drugs in various prescriptions. The drawbacks with NSAIDs in its long-term usage are gastric irritation, bleeding, and perforation. Prodrug approach is a commonly used method to overcome these side effects. In this study, the reported prodrugs of mefenamic acid were utilized to validate the molecular docking simulation process by comparing obtained in silico results with the reported in vivo results. The molecules were evaluated for their binding affinity against human cyclooxygenase-2 enzyme as well as their pharmacokinetics profile is predicted on the basis of Lipinski's and Veber rule. The in silico result showed high degree similarity with experimental results. This confirms the efficiency and reliability of the molecular docking technique for identification of potential lead compounds.


Subject(s)
Cyclooxygenase 2 Inhibitors/pharmacology , Cyclooxygenase 2/metabolism , Mefenamic Acid/pharmacology , Molecular Docking Simulation , Prodrugs/pharmacology , Binding Sites/drug effects , Cyclooxygenase 2 Inhibitors/chemistry , Humans , Ligands , Mefenamic Acid/chemistry , Molecular Structure , Prodrugs/chemistry
7.
Bioorg Med Chem ; 27(7): 1327-1340, 2019 04 01.
Article in English | MEDLINE | ID: mdl-30795991

ABSTRACT

Novel hybrids bearing a 2-aminopyrimidine (2-AP) moiety linked to substituted 1,3,4-oxadiazoles were designed, synthesized and biologically evaluated. Among the developed compounds, 28 noncompetitively inhibited human acetylcholinesterase (hAChE; pIC50 = 6.52; Ki = 0.17 µM) and showed potential in vitro antioxidant activity (60.0%) when evaluated using the Ellman's and DPPH assays, respectively. Compound 28 competitively displaced propidium iodide (PI) from the peripheral anionic site (PAS) of hAChE (17.6%) and showed high blood-brain barrier (BBB) permeability, as observed in the PAMPA-BBB assay. Additionally, compound 28 inhibited hAChE-induced Aß aggregation in a concentration-dependent manner according to the thioflavin T assay and was devoid of neurotoxic liability towards SH-SY5Y cell lines, as demonstrated by the MTT assay. The behavioral studies of compound 28 in mice showed a significant reversal of scopolamine-induced amnesia, as observed in Y-maze and passive avoidance tests. Furthermore, compound 28 exhibited significant AChE inhibition in the brain in ex vivo studies. An evaluation of oxidative stress biomarkers revealed the antioxidant potential of 28. Moreover, in silico molecular docking and dynamics simulation studies were used as a computational tool to evaluate the interactions of compound 28 with the active site residues of hAChE.


Subject(s)
Cholinesterase Inhibitors/pharmacology , Cognitive Dysfunction/drug therapy , Drug Design , Oxadiazoles/pharmacology , Pyrimidines/pharmacology , Acetylcholinesterase/metabolism , Animals , Butyrylcholinesterase/metabolism , Cell Line , Cholinesterase Inhibitors/chemical synthesis , Cholinesterase Inhibitors/chemistry , Cognitive Dysfunction/metabolism , Dose-Response Relationship, Drug , Humans , Mice , Models, Molecular , Molecular Structure , Oxadiazoles/chemical synthesis , Oxadiazoles/chemistry , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Structure-Activity Relationship
8.
Int J Oncol ; 54(4): 1306-1316, 2019 04.
Article in English | MEDLINE | ID: mdl-30720134

ABSTRACT

Trans­3,4',5­trihydroxystilbene (resveratrol) is a naturally occurring polyphenolic phytoalexin with marked anticancer activities, and is mainly found in grapes, berries and peanuts. However, due to a low bioavailability, it has not progressed to clinical practice for cancer treatment. Therefore, the aims of the present study were to examine the anticancer activities of the resveratrol derivative, triacetyl resveratrol (TCRV), in pancreatic cancer cells. Apoptosis was measured by fluorescence­activated cell sorting and terminal deoxynucleotidyl transferase (TdT)­mediated dUTP nick­end labeling assays. Gene expression was measured by reverse transcription­quantitative polymerase chain reaction. TCRV inhibited colony formation and induced apoptosis through caspase­3 activation in human pancreatic cancer AsPC­1 and PANC­1 cells, whereas it exerted no effect on human pancreatic normal ductal epithelial cells (HPNE). TCRV inhibited epithelial­mesenchymal transition (EMT) by upregulating the expression of E­cadherin and suppressing the expression of N­cadherin and the transcription factors, Snail, Slug and Zeb1. TCRV inhibited Zeb1 3'UTR­luciferase activity through the upregulation of microRNA (miR)­200 family members. The inhibitory effects of TCRV on pancreatic cancer cell migration and invasion were counteracted by anti­miR­200 family members. The inhibitory effects of TCRV on EMT and the induction of apoptosis were exerted through the suppression of the sonic hedgehog (Shh) pathway, and through the modulation of cyclin D1 and Bcl­2 expression. The hyperactivation of the Shh pathway by either Shh protein or Gli1 overexpression abrogated the biological effects of TCRV. Taken together, the results of this study demonstrate that TCRV inhibits pancreatic cancer growth and EMT by targeting the Shh pathway and its downstream signaling mediators. TCRV inhibited EMT through the upregulation of miR­200 family members. Since TCRV effectively inhibited the growth of human pancreatic cancer cells by modulating the Shh pathway, without affecting the growth of HPNE cells, our findings suggest the possible use of TCRV as a promising candidate for the treatment and/or prevention of pancreatic cancer.


Subject(s)
MicroRNAs/genetics , Pancreatic Neoplasms/genetics , Resveratrol/pharmacology , Signal Transduction/drug effects , Up-Regulation , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Epithelial-Mesenchymal Transition/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Hedgehog Proteins/genetics , Humans , Pancreatic Neoplasms/drug therapy , Resveratrol/analogs & derivatives
9.
Prog Neurobiol ; 174: 53-89, 2019 03.
Article in English | MEDLINE | ID: mdl-30599179

ABSTRACT

AD is a progressive neurodegenerative disorder and a leading cause of dementia in an aging population worldwide. The enormous challenge which AD possesses to global healthcare makes it as urgent as ever for the researchers to develop innovative treatment strategies to fight this disease. An in-depth analysis of the extensive available data associated with the AD is needed for a more comprehensive understanding of underlying molecular mechanisms and pathophysiological pathways associated with the onset and progression of the AD. The currently understood pathological and biochemical manifestations include cholinergic, Aß, tau, excitotoxicity, oxidative stress, ApoE, CREB signaling pathways, insulin resistance, etc. However, these hypotheses have been criticized with several conflicting reports for their involvement in the disease progression. Several issues need to be addressed such as benefits to cost ratio with cholinesterase therapy, the dilemma of AChE selectivity over BChE, BBB permeability of peptidic BACE-1 inhibitors, hurdles related to the implementation of vaccination and immunization therapy, and clinical failure of candidates related to newly available targets. The present review provides an insight to the different molecular mechanisms involved in the development and progression of the AD and potential therapeutic strategies, enlightening perceptions into structural information of conventional and novel targets along with the successful applications of computational approaches for the design of target-specific inhibitors.


Subject(s)
Alzheimer Disease/physiopathology , Alzheimer Disease/metabolism , Animals , Humans
10.
Bioorg Chem ; 85: 82-96, 2019 04.
Article in English | MEDLINE | ID: mdl-30605887

ABSTRACT

A series of novel piperazine tethered biphenyl-3-oxo-1,2,4-triazine derivatives were designed, and synthesized. Amongst the synthesized analogs, compound 6g showed significant non-competitive inhibitory potential against acetylcholinesterase (AChE, IC50; 0.2 ±â€¯0.01 µM) compared to standard donepezil (AChE, IC50: 0.1 ±â€¯0.002 µM). Compound 6g also exhibited significant displacement of propidium iodide from the peripheral anionic site (PAS) of AChE (22.22 ±â€¯1.11%) and showed good CNS permeability in PAMPA-BBB assay (Pe(exp), 6.93 ±â€¯0.46). The in vivo behavioral studies of compound 6g indicated significant improvement in cognitive dysfunctions against scopolamine-induced amnesia mouse models. Further, ex vivo studies showed a significant AChE inhibition and reversal of the scopolamine-induced oxidative stress by compound 6g. Moreover, molecular docking and dynamics simulations of compound 6g showed a consensual binding affinity and active site interactions with the PAS and active catalytic site (CAS) residues of AChE.


Subject(s)
Cholinesterase Inhibitors/pharmacology , Learning/drug effects , Memory/drug effects , Nootropic Agents/pharmacology , Piperazines/pharmacology , Triazines/pharmacology , Acetylcholinesterase/chemistry , Acetylcholinesterase/metabolism , Animals , Antioxidants/chemical synthesis , Antioxidants/metabolism , Antioxidants/pharmacology , Biphenyl Compounds/chemical synthesis , Biphenyl Compounds/metabolism , Biphenyl Compounds/pharmacology , Catalytic Domain , Cell Line, Tumor , Cholinesterase Inhibitors/chemical synthesis , Cholinesterase Inhibitors/metabolism , Drug Design , Humans , Male , Mice , Molecular Docking Simulation , Molecular Dynamics Simulation , Nootropic Agents/chemical synthesis , Nootropic Agents/metabolism , Piperazines/chemical synthesis , Piperazines/metabolism , Protein Binding , Torpedo , Triazines/chemical synthesis , Triazines/metabolism
11.
Bioorg Chem ; 82: 211-223, 2019 02.
Article in English | MEDLINE | ID: mdl-30326403

ABSTRACT

Based on the quantitative structure-activity relationship (QSAR), some novel p-aminobenzoic acid derivatives as promising cholinesterase enzyme inhibitors were designed, synthesized, characterized and evaluated to enhance learning and memory. The in vitro enzyme kinetic study of the synthesized compounds revealed the type of inhibition on the respective acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. The in vivo studies of the synthesized compounds exhibited significant reversal of cognitive deficits in the animal models of amnesia as compared to standard drug donepezil. Further, the ex vivo studies in the specific brain regions like the hippocampus, hypothalamus, and prefrontal cortex regions also exhibited AChE inhibition comparable to standard donepezil. The in silico molecular docking and dynamics simulations studies of the most potent compound 22 revealed the consensual interactions at the active site pocket of the AChE.


Subject(s)
Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/therapeutic use , Nootropic Agents/therapeutic use , para-Aminobenzoates/therapeutic use , Acetylcholinesterase/chemistry , Acetylcholinesterase/metabolism , Animals , Brain/metabolism , Butyrylcholinesterase/chemistry , Butyrylcholinesterase/metabolism , Catalytic Domain , Cholinesterase Inhibitors/chemical synthesis , Cholinesterase Inhibitors/chemistry , Cholinesterase Inhibitors/toxicity , Drug Design , Female , Kinetics , Male , Memory/drug effects , Molecular Docking Simulation , Molecular Dynamics Simulation , Molecular Structure , Nootropic Agents/chemical synthesis , Nootropic Agents/chemistry , Nootropic Agents/toxicity , Quantitative Structure-Activity Relationship , Rats , Semicarbazones/chemical synthesis , Semicarbazones/chemistry , Semicarbazones/therapeutic use , Semicarbazones/toxicity , para-Aminobenzoates/chemical synthesis , para-Aminobenzoates/chemistry , para-Aminobenzoates/toxicity
12.
Eur J Med Chem ; 163: 116-135, 2019 Feb 01.
Article in English | MEDLINE | ID: mdl-30503937

ABSTRACT

Based on the Gaussian-based quantitative structure-activity relationship (QSAR) and virtual screening (VS) processes, some promising acetylcholinesterase inhibitors (AChEIs) having antioxidant potential were designed synthesized, characterized, and evaluated for their ability to enhance learning and memory. The synthesized phenyl benzoxazole derivatives exhibited significant antioxidant potential and AChE inhibitory activity, whereas the antioxidant potential of compound 34 (49.6%) was observed significantly better than standard donepezil (<10%) and parallel to ascorbic acid (56.6%). Enzyme kinetics study of most potent compound 34 (AChE IC50 = 0.363 ±â€¯0.017 µM; Ki = 0.19 ±â€¯0.03 µM) revealed the true nature and competitive type of inhibition on AChE. The compound 34 was further assessed for in vivo and ex vivo studies and the results showed the significant reversal of cognitive deficits and antioxidant potential at the dose of 5 mg/kg comparable to standard drug donepezil.


Subject(s)
Benzoxazoles/chemical synthesis , Cholinesterase Inhibitors/pharmacology , Drug Design , Antioxidants/chemical synthesis , Antioxidants/pharmacology , Benzoxazoles/pharmacology , Cholinesterase Inhibitors/therapeutic use , Humans , Learning/drug effects , Memory/drug effects , Pharmacokinetics , Quantitative Structure-Activity Relationship
13.
Med Chem ; 14(4): 409-426, 2018.
Article in English | MEDLINE | ID: mdl-29336266

ABSTRACT

BACKGROUND: Nipecotic acid is considered to be one of the most potent inhibitors of neuronal and glial γ-aminobutyric acid (GABA) uptake in vitro. However, nipecotic acid does not readily cross the blood-brain barrier (BBB) following peripheral administration, owing to its hydrophilic nature. OBJECTIVE: A series of substituted acetonaphthones tethered nipecotic acid derivatives were designed and synthesized with an aim to improve the lipophilicity and the blood-brain barrier (BBB) permeation. METHODS: Synthesized compounds were tested in mice models of PTZ, pilocarpine, and DMCM induced epilepsy, in vivo. The rota-rod test was performed to determine the acute neurotoxicity of the potential leads (4a, 4b, and 4i). These potential hybrids were also evaluated for their ability to cross the BBB by an in vitro parallel artificial membrane permeability BBB assay (PAMPA-BBB). The leads were subjected to in silico molecular docking and dynamics studies on homology modelled protein of human GABA (γ-amino butyric acid) transporter 1 (GAT1) and prediction of their pharmacokinetic properties. RESULT: Amongst the synthesized derivatives, compounds 3a, 3b, 3i, 4a, 4b, and 4i exhibited increased latency of seizures against subcutaneous pentylenetetrazole (scPTZ) induced seizures in mice. Derivatives 4a, 4b, 4i were more effective compared to nipecotic acid ester counterparts 3a, 3b and 3i placing the importance of the presence of free carboxyl group in the centre. The findings revealed that 4i was comparatively more permeable (Pe= 8.89) across BBB than the standard tiagabine (Pe= 7.86). In silico studies proved the consensual interactions of compound 4i with the active binding pocket. CONCLUSION: Some nipecotic acid-acetonaphthone hybrids with considerable anti-epileptic activity, drug like properties and the ability to permeate the BBB have been successfully synthesized.


Subject(s)
Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Naphthalenes/therapeutic use , Nipecotic Acids/therapeutic use , Animals , Anticonvulsants/chemical synthesis , Anticonvulsants/chemistry , Blood-Brain Barrier/metabolism , Disease Models, Animal , Drosophila , Drug Design , Female , GABA Plasma Membrane Transport Proteins/chemistry , GABA Uptake Inhibitors/chemical synthesis , GABA Uptake Inhibitors/chemistry , GABA Uptake Inhibitors/therapeutic use , Humans , Hydrophobic and Hydrophilic Interactions , Male , Mice , Molecular Docking Simulation , Molecular Dynamics Simulation , Naphthalenes/chemical synthesis , Naphthalenes/chemistry , Nipecotic Acids/chemical synthesis , Nipecotic Acids/chemistry , Tiagabine
14.
Bioorg Med Chem ; 25(16): 4424-4432, 2017 08 15.
Article in English | MEDLINE | ID: mdl-28669741

ABSTRACT

Some novel indolizine derivatives were synthesized by bioisosteric modification of imidazo[1,2-a]pyridine for anti-inflammatory activity. The physicochemical characterization and structure of compounds were elucidated by state of the art spectroscopic technique. Induced fit docking was performed for initial screening to elucidate the interactions with corresponding amino acids of cyclooxygenase (COX-1, COX-2) and lipoxygenase (LOX) enzymes. The target compounds 53-60 were then evaluated against in vivo carrageenan and arachidonic acid induced rat paw edema models for anti-inflammatory activity. Amongst all the synthesized derivatives, compound 56 showed the significant anti-inflammatory activity in both rat paw edema models with very less ulcerogenic liability in comparison to standard diclofenac, celecoxib, and zileuton. The compounds 56 was further assessed to observe in vitro enzyme inhibition assay on both cyclooxygenase and lipoxygenase enzyme where it showed a preferential and selective non-competitive enzyme inhibition towards the COX-2 (IC50=14.91µM, Ki=0.72µM) over COX-1 (IC50>50µM) and a significant non-competitive inhibition of soybean lipoxygenase enzyme (IC50=13.09µM, Ki=0.92µM). Thus, in silico, in vivo, and in vitro findings suggested that the synthesized indolizine compound 56 has a dual COX-2 and LOX inhibition characteristic and parallel in vivo anti-inflammatory activity in comparison to the standard drugs.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Indolizines/pharmacology , Lipoxygenase Inhibitors/pharmacology , Lipoxygenase/metabolism , Prostaglandin-Endoperoxide Synthases/metabolism , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Arachidonic Acid , Carrageenan , Cyclooxygenase Inhibitors/chemical synthesis , Cyclooxygenase Inhibitors/chemistry , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Design , Edema/chemically induced , Edema/drug therapy , Female , Indolizines/chemical synthesis , Indolizines/chemistry , Lipoxygenase Inhibitors/chemical synthesis , Lipoxygenase Inhibitors/chemistry , Male , Mice , Molecular Structure , Rats , Structure-Activity Relationship , Ulcer/chemically induced , Ulcer/drug therapy
15.
Bioorg Med Chem ; 25(4): 1471-1480, 2017 02 15.
Article in English | MEDLINE | ID: mdl-28126439

ABSTRACT

Series of some 3,5-dimethoxy-N-methylenebenzenamine and 4-(methyleneamino)benzoic acid derivatives comprising of N-methylenebenzenamine nucleus were designed, synthesized, characterized, and assessed for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE) inhibitory, and antioxidant activity thereby improving learning and memory in rats. The IC50 values of all the compound along with standard were determined on AChE and BChE enzyme. The free radical scavenging activity was also assessed by in vitro DPPH (2,2-diphenyl-1-picryl-hydrazyl) and hydrogen peroxide radical scavenging assay. The selective inhibitions of all compounds were observed against AChE in comparison with standard donepezil. The enzyme kinetic study of the most active compound 4 indicated uncompetitive AChE inhibition. The docking studies of compound 4 exhibited the worthy interaction on active-site gorge residues Phe330 and Trp279 responsible for its high affinity towards AChE, whereas lacking of the BChE inhibition was observed due to a wider gorge binding site and absence of important aromatic amino acids interactions. The ex vivo study confirmed AChE inhibition abilities of compound 4 at brain site. Further, a considerable decrease in escape latency period of the compound was observed in comparison with standard donepezil through in vivo Spatial Reference Memory (SRM) and Spatial Working Memory (SWM) models which showed the cognition-enhancing potential of compound 4. The in vivo reduced glutathione (GSH) estimation on rat brain tissue homogenate was also performed to evaluate free radical scavenging activity substantiated the antioxidant activity in learning and memory.


Subject(s)
Acetylcholinesterase/metabolism , Antioxidants/pharmacology , Cholinesterase Inhibitors/pharmacology , Drug Design , Learning/drug effects , Memory/drug effects , Schiff Bases/pharmacology , Administration, Oral , Animals , Antioxidants/administration & dosage , Antioxidants/chemistry , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/chemistry , Dose-Response Relationship, Drug , Molecular Docking Simulation , Molecular Structure , Rats , Schiff Bases/administration & dosage , Schiff Bases/chemistry , Structure-Activity Relationship
16.
Open Med Chem J ; 11: 146-195, 2017.
Article in English | MEDLINE | ID: mdl-29387273

ABSTRACT

INTORODUCTION: Prodrug approach deals with chemical biotransformation or enzymatic conversion or involves inactive or less active bio-reversible derivatives of active drug molecules. They have to pass through enzymatic or chemical biotransformation before eliciting their pharmacological action. METHODS & MATERIALS: The two different pharmacophores combine to give synergistic activity or may help in targeting the active drug to its target. Prodrug super seeds the problems of prodrug designing, for example solubility enhancement, bioavailability enhancement, chemical stability improvement, presystemic metabolism, site specific delivery, toxicity masking, improving patient acceptance, or eradicating undesirable adverse effects. RESULTS: As an outcome the search for a prodrug or mutual prodrug with reduced toxicity has continued during recent years. This present review emphasizes the common help to revamp physiochemical, pharmaceutical and therapeutic effectiveness of drugs. CONCLUSION: This gives the researcher a common platform where they can find prodrugs of commonly used NSAIDs to overcome the gastrointestinal toxicity (irritation, ulcergenocity and bleeding).

17.
Pak J Pharm Sci ; 27(4): 917-23, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25015460

ABSTRACT

Gastrosparing novel prodrugs (MAM and MAT) synthesized consisted of mefenamic acid (MA) with menthol (M) and thymol (T). Structural characterizations of synthesized esters were done by Infra red spectroscopy (IR), proton nuclear magnetic resonance (1HNMR), mass spectroscopy. After evaluation of pharmacological i.e. anti-inflammatory, analgesic and ulcerogenic activities, the preformulation studies were undertaken. Based on these a few formulation (suspensions) were designed and prepared. The formulated suspensions were evaluated for content uniformity, sedimentation volume, recovery studies, redispersibility, viscosity, pH, particle size, zeta potential, effect of temperature and in-vitro dissolution rate. All the above parameters were found to be within the limit these indicated that the synthesized esters are good candidate for liquid dosage form. Thus it can be concluded synthesized prodrugs can be formulated in suspension form.


Subject(s)
Mefenamic Acid/chemistry , Prodrugs/chemistry , Chemistry, Pharmaceutical , Hydrogen-Ion Concentration , Solubility , Suspensions
18.
Med Chem ; 10(8): 800-9, 2014.
Article in English | MEDLINE | ID: mdl-24693874

ABSTRACT

Novel N3 aryl/heteroaryl substituted 2-((benzyloxy and phenylthio) methyl) 6,7-dimethoxyquinazolin-4(3H)- ones (8a-8l) were synthesized and evaluated for their anticonvulsant activity using various models of epilepsy, such as maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) and intracerebroventricular AMPA (α-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid)-induced seizures in mice. The rotarod test has been used to determine the acute neurotoxicity. Further, the serum enzymatic activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were assessed along with histopathological examination of liver. Among all the derivatives, compound 8f displayed significant activity profile based on the overall magnitude of activity and minimum neurotoxicity.


Subject(s)
Anticonvulsants/chemical synthesis , Drug Design , Quinazolinones/chemical synthesis , Seizures/drug therapy , Alanine Transaminase/blood , Animals , Anticonvulsants/chemistry , Anticonvulsants/pharmacology , Aspartate Aminotransferases/blood , Convulsants/administration & dosage , Disease Models, Animal , Drug Evaluation, Preclinical , Electroshock , Female , Injections, Intraventricular , Injections, Subcutaneous , Liver/drug effects , Liver/pathology , Male , Mice , Motor Activity/drug effects , Pentylenetetrazole/administration & dosage , Quinazolinones/chemistry , Quinazolinones/pharmacology , Rats , Rotarod Performance Test , Seizures/blood , Seizures/chemically induced , Seizures/physiopathology , Structure-Activity Relationship , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/administration & dosage , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/adverse effects
19.
Acta Pol Pharm ; 70(5): 905-11, 2013.
Article in English | MEDLINE | ID: mdl-24147370

ABSTRACT

A novel mutual prodrug (MA-P) consisting of mefenamic acid (MA) and paracetamol (P) has been synthesized as a gastrosparing NSAID, devoid of ulcerogenic side effects. The structure of synthesized drug was confirmed by elemental analysis, infrared spectroscopy, 1H NMR spectroscopy and mass spectrometry.The kinetics of ester hydrolysis was studied by HPLC at pH 2, pH 7.4 as well as in human plasma. The pharmacological activities (anti-inflammatory, analgesic and ulcerogenic) were evaluated for the synthesized drug. The ulcerogenic reduction in terms of gastric wall mucosa, hexosamine and total proteins were also measured in glandular stomach of rats. The results indicated that MA-P ester has better ulcer index than the parent drug.


Subject(s)
Acetaminophen/chemistry , Analgesics, Non-Narcotic/chemistry , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Mefenamic Acid/chemical synthesis , Mefenamic Acid/pharmacology , Prodrugs/chemical synthesis , Prodrugs/pharmacology , Acetaminophen/pharmacology , Analgesics, Non-Narcotic/pharmacology , Animals , Carrageenan , Edema/chemically induced , Edema/prevention & control , Female , Humans , Hydrolysis , In Vitro Techniques , Indicators and Reagents , Magnetic Resonance Spectroscopy , Male , Mefenamic Acid/blood , Mice , Pain Measurement/drug effects , Rats , Solubility , Spectrophotometry, Infrared , Spectrophotometry, Ultraviolet , Spectroscopy, Fourier Transform Infrared , Stomach Ulcer/chemically induced
20.
Bioorg Med Chem ; 21(17): 5451-60, 2013 Sep 01.
Article in English | MEDLINE | ID: mdl-23810675

ABSTRACT

Some new semicarbazones of 4-aminopyridine were synthesized and evaluated for antiamnesic, cognition enhancing and anticholinesterase activities. The results illustrated a significant cognition enhancing effect on elevated plus maze model with a significant reversal of scopolamine-induced amnesia. A significant inhibition in acetycholinesterase (AChE) activity by all the synthesized compounds in specific brain regions that is, prefrontal cortex, hippocampus and hypothalamus was observed. Compound 4APi exhibited significant antiamnesic and cognition enhancing activity which was comparable with standard drug donepezil. Its enzyme kinetic study revealed a non-competitive inhibition of AChE and a competitive inhibition of butyrylcholinesterase (BChE). Docking studies predicted the binding modes of these compounds in AChE active site, which were further processed for molecular dynamics simulation for calculating binding free energies using Molecular Mechanics-Generalized Born Surface Area (MM/GBSA). All the computational study confirmed their consensual interaction with AChE justifying the experimental outcome.


Subject(s)
Aminopyridines/chemistry , Cholinesterase Inhibitors/chemical synthesis , Semicarbazones/chemistry , Acetylcholinesterase/chemistry , Acetylcholinesterase/metabolism , Amnesia/chemically induced , Amnesia/drug therapy , Animals , Behavior, Animal/drug effects , Binding Sites , Brain/enzymology , Butyrylcholinesterase/chemistry , Butyrylcholinesterase/metabolism , Catalytic Domain , Cholinesterase Inhibitors/pharmacology , Cholinesterase Inhibitors/therapeutic use , Kinetics , Molecular Docking Simulation , Rats , Semicarbazones/pharmacology , Semicarbazones/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...